Back to Search Start Over

Ipilimumab for Patients with Relapse after Allogeneic Transplantation.

Authors :
Davids, Matthew S
Davids, Matthew S
Kim, Haesook T
Bachireddy, Pavan
Costello, Caitlin
Liguori, Rebecca
Savell, Alexandra
Lukez, Alexander P
Avigan, David
Chen, Yi-Bin
McSweeney, Peter
LeBoeuf, Nicole R
Rooney, Michael S
Bowden, Michaela
Zhou, Chensheng W
Granter, Scott R
Hornick, Jason L
Rodig, Scott J
Hirakawa, Masahiro
Severgnini, Mariano
Hodi, F Stephen
Wu, Catherine J
Ho, Vincent T
Cutler, Corey
Koreth, John
Alyea, Edwin P
Antin, Joseph H
Armand, Philippe
Streicher, Howard
Ball, Edward D
Ritz, Jerome
Bashey, Asad
Soiffer, Robert J
Leukemia and Lymphoma Society Blood Cancer Research Partnership
Davids, Matthew S
Davids, Matthew S
Kim, Haesook T
Bachireddy, Pavan
Costello, Caitlin
Liguori, Rebecca
Savell, Alexandra
Lukez, Alexander P
Avigan, David
Chen, Yi-Bin
McSweeney, Peter
LeBoeuf, Nicole R
Rooney, Michael S
Bowden, Michaela
Zhou, Chensheng W
Granter, Scott R
Hornick, Jason L
Rodig, Scott J
Hirakawa, Masahiro
Severgnini, Mariano
Hodi, F Stephen
Wu, Catherine J
Ho, Vincent T
Cutler, Corey
Koreth, John
Alyea, Edwin P
Antin, Joseph H
Armand, Philippe
Streicher, Howard
Ball, Edward D
Ritz, Jerome
Bashey, Asad
Soiffer, Robert J
Leukemia and Lymphoma Society Blood Cancer Research Partnership
Source :
The New England journal of medicine; vol 375, iss 2, 143-153; 0028-4793
Publication Year :
2016

Abstract

BackgroundLoss of donor-mediated immune antitumor activity after allogeneic hematopoietic stem-cell transplantation (HSCT) permits relapse of hematologic cancers. We hypothesized that immune checkpoint blockade established by targeting cytotoxic T-lymphocyte-associated protein 4 with ipilimumab could restore antitumor reactivity through a graft-versus-tumor effect.MethodsWe conducted a phase 1/1b multicenter, investigator-initiated study to determine the safety and efficacy of ipilimumab in patients with relapsed hematologic cancer after allogeneic HSCT. Patients received induction therapy with ipilimumab at a dose of 3 or 10 mg per kilogram of body weight every 3 weeks for a total of 4 doses, with additional doses every 12 weeks for up to 60 weeks in patients who had a clinical benefit.ResultsA total of 28 patients were enrolled. Immune-related adverse events, including one death, were observed in 6 patients (21%), and graft-versus-host disease (GVHD) that precluded further administration of ipilimumab was observed in 4 patients (14%). No responses that met formal response criteria occurred in patients who received a dose of 3 mg per kilogram. Among 22 patients who received a dose of 10 mg per kilogram, 5 (23%) had a complete response, 2 (9%) had a partial response, and 6 (27%) had decreased tumor burden. Complete responses occurred in 4 patients with extramedullary acute myeloid leukemia and 1 patient with the myelodysplastic syndrome developing into acute myeloid leukemia. Four patients had a durable response for more than 1 year. Responses were associated with in situ infiltration of cytotoxic CD8+ T cells, decreased activation of regulatory T cells, and expansion of subpopulations of effector T cells in the blood.ConclusionsOur early-phase data showed that administration of ipilimumab was feasible in patients with recurrent hematologic cancers after allogeneic HSCT, although immune-mediated toxic effects and GVHD occurred. Durable responses were observed in ass

Details

Database :
OAIster
Journal :
The New England journal of medicine; vol 375, iss 2, 143-153; 0028-4793
Notes :
application/pdf, The New England journal of medicine vol 375, iss 2, 143-153 0028-4793
Publication Type :
Electronic Resource
Accession number :
edsoai.on1378688087
Document Type :
Electronic Resource